Background: Hemodialysis with polymethylmetacrylate (PMMA) membrane dialyzers allows unique protein adsorption. New PMMA dialyzers should demonstrate equivalent protein adsorption, but improved hemocompatibility.
Background
Hemodialysis with polymethylmetacrylate (PMMA) dialyzers allows unique protein adsorption [1, 2] . Clinically, hemodialysis with PMMA dialyzers is associated with the relief of dialysis-induced itching [3, 4] and improvement of nutrition [5] . A new PMMA dialyzer was developed to improve hemocompatibility while maintaining the amount of protein adsorption. The present study aimed to determine the basic properties of the new membrane and its performance in solute removal and peripheral circulation under standard clinical conditions.
Methods

Subjects
We evaluated the new PMMA dialyzer; "Filtryzer® NF" (NF) and compared it with the conventional PMMA dialyzer; "Filtryzer® BG" (BG). The performance of the dialyzers were compared in experimental and clinical studies. For the testing in vitro, hollow fiber membranes were cut from the dialyzers and used as samples. For the clinical testing, dialyzers with a 1.6 m 2 membrane surface area were used. Technical data on BG and NF are summarized in Table 1 .
Membrane analysis Blood component adhesion
The hollow fiber membranes were longitudinally cut to expose the inner surface and then incubated with fresh human whole blood containig 50 U/mL of heparin (Heparin Sodium Injection, Ajinomoto, Tokyo, Japan) for 1 h at 37 ℃ with continuous agitation. After washing with phosphate-buffered saline (PBS), the samples were fixed with 25% glutaraldehyde (Sigma-Aldrich) and observed by field emission scanning electron microscopy (S-800, Hitachi High-Tech Fielding Corp., Tokyo, Japan) to count the number of adhered platelets. The blood was obtained from volunteers after ethical review and approval by Toray Industries, Inc.
Activation of platelets
We prepared the mini modules of NF, BG. The mini-module had a length of 120 mm and a diameter of 5 mm, and contained 48 hollow fibers. Membrane surface area of mini module was 3619 mm2. 6.5 mL of fresh human blood, including the 15% acid citrate dextrose solution (ACD) as an anti-coagulant, was circulated to it at 1.0 mL/min for 30 min. The collected blood was allowed to stand in ice water for 15 min and centrifuged at 2000g at 4°C for 30 min. The β-thromboglobulin (β-TG) concentration in the resulting plasma was determined by the enzyme immunoassay (EIA) method.
Electrophoresis of the adsorbed proteins
We prepared the mini modules of polysulfone membrane dialyzer "Toraylight® NV-U" as a reference, in addition to NF and BG. 6.5 mL of human serum (Human Serum type AB, Sigma-Aldrich) was circulated to it at 1.0 mL/min for 4 h. After circulation, the column was washed with 20 mL of PBS. The hollow fiber membranes were removed and cut into 5-mm-long pieces, which were then immersed in 50% acetic acid (017-00251, Wako Pure Chemical Industries, Ltd., Osaka, Japan) for 24 h to extract the adsorbed proteins. The extracted samples were freeze-dried and dissolved in PBS. We determined the quantity of protein in the samples using the BCA Assay (Pierce BCA Protein Assay Kit, Takara Bio, Otsu, Japan). Next, the samples were processed into aliquots with 0.2 g of protein each in the same volume of sample buffer (Tris-aspartic acid sample buffer, TEFCO, Aomori, Japan) and were heated at 95°C for 5 min. The samples were electrophoresed through a gel (4-12% LS-PAGE mini, TEFCO) at 100 V for 1 h in Tris-aspartic acid running buffer (TEFCO). The gels were stained with Coomassie Brilliant Blue (PhastGel Blue R 40Tablets, Pharmacia Biotech, Uppsala, Sweden) and silver staining (Silver Staining II Kit, Wako) and then imaged.
Clinical study Subjects
Six anuric patients (five males and one female) with no inflammatory signs who were on maintenance dialysis were enrolled. Subject characteristics included a mean age of 69 ± 16 years and a mean duration of dialysis therapy of 9.1 ± 2.5 years. Underlying conditions were glomerulonephritis in two patients, nephrosclerosis in two, diabetic nephropathy in one, and unknown in one. All subjects had undergone hemodialysis with Filtryzer ® BK (BK) before enrolling in the study. All patients were confirmed to have no clinical findings or data on the ankle-brachial pressure index (ABI), which is indicative of arterial stenosis or obstruction of the lower 
Methods
As shown in Fig. 1 , the six subjects were treated with NF and BG for 3 months each in a crossover design. The last dialysis treatment using each dialyzer for 3 months, the amount of solute removal, percent changes in platelet count during dialysis, changes in peripheral circulation, and any dialysis-related complaints from the patients were evaluated. The prescription dialysis was performed with a blood flow rate of 270 mL/min, dialyzate flow rate of 500 mL/min, and dialysis time of 4 h. The solute removal capacity was evaluated based on the percent reduction of the blood concentrations of urea nitrogen, creatinine, uric acid, inorganic phosphorus, β 2 microglobulin (β 2 MG), and α 1 microglobulin (α 1 MG) and the total amounts of albumin in the effluent dialyzate. The peripheral circulation was evaluated with PAD-3000® (Kaneka Medix, Osaka, Japan). The skin perfusion pressure (SPP) of the sole of the right foot [6] was measured before dialysis and at every hour during dialysis, and the rate of change was evaluated based on the value before dialysis. SPP measurement was performed twice a week with each dialyzer.
In addition, at the same time of SPP measurement, systolic blood pressure was also measured. Dialysis-related side effects, including itching, distraction, malaise, headache, hypotension, fatigue after dialysis, and appetite, were evaluated for each dialyzer. Each side effect was evaluated on a 5-grade scale (0-4), with lower scores meaning fewer complaints.
Statistical analysis
Student's t tests were used to compare activation of platelets in vitro and laboratory results from the clinical study between groups. Results of the investigation of unidentified complaints were tested with Friedman's test. The analytical data are shown as the mean ± standard deviation. P values <0.05 were considered statistically significant.
Results
Membrane analysis
The number of adhered platelets in vitro was at least 100-fold lower on NF than on BG (Fig. 2) . When the β-TG level, as a platelet activation marker, was evaluated in vitro, that of NF was 30% lower than BG (Fig. 3) . The molecular weights of the proteins adsorbed on NF and BG were nearly equivalent, as assessed by electrophoresis (Fig. 4) .
Clinical study
The percent reduction of small molecules and lowmolecular-weight proteins in the blood before and after dialysis is shown in Fig. 5 , and the total amount of albumin in the effluent dialyzate is shown in Fig. 6 . There were no significant differences in any of these parameters between NF and BG.
During dialysis, the percent changes in platelet count were (for NF and BG, respectively) 97.1 and 86.1% after 15 min of dialysis, 96.5 and 85.1% after 30 min, 97.3 and 88.3% after 1 h, and 99.6 and 90.1% after 4 h. The changes in platelet count during dialysis were significantly smaller with NF than with BG (Fig. 7) .
The systolic blood pressure during dialysis was shown in Fig. 8a . There were no significant difference between NF and BG, and no cases of intradialytic hypotension which required intervention.
Peripheral circulation was evaluated through changes in SPP during dialysis and compared between groups. The SPP values were 69.6 ± 12.2 mmHg before the start of dialysis, 69.8 ± 11.5 mmHg after 1 h (percent change, +0.6 ± 7.7%), 70.4 ± 10.0 mmHg (+1.7 ± 9.7%) after 2 h, 67.7 ±14.4 mmHg (−2.8 ± 11.8%) after 3 h, and 64.6 ± 14.5 mmHg (−7.7 ± 11.1%) after 4 h with NF, indicating that the SPP was maintained and did not significantly change during dialysis. With BG, the SPP values were 77.7 ± 10.4 mmHg before the start of dialysis, 71.4 ± 14.2 mmHg (−7.6 ± 16.5%) after 1 h, 66.9 ± 12.7 mmHg (−13.4 ± 15.6%) after 2 h, 65.4 ± 10.4 mmHg (−15.7 ± 9.9%) after 3 h, and 63.6 ± 9.6 mmHg Fig. 1 The design of clinical study Fig. 2 The number of adhered platelets on NF and BG in vitro (−17.9 ± 9.4%) after 4 h, indicating significant decreases in the SPP after 3 and 4 h compared with before starting dialysis. The percent changes in SPP were significantly smaller at 2 and 3 h with NF compared with BG (Fig. 8b) . Data on the dialysis-related side effects are shown in Fig. 9 . There were no significant differences in any individual items or in the mean total score for the two groups, but the mean score of the seven items tended to be lower with NF.
Discussion
The number of adhered platelets on NF was at least 100-fold lower than that on BG (Fig. 2) , and the platelet activation of NF was 30% lower than that of BG (Fig. 3) . On the other hand, no substantial differences were found in the amount of adsorbed proteins or their molecular weight between NF and BG. These results indicate that protein adsorption pattern by the hollow fiber NF was similar to that of BG (Fig. 4) . (Although the used blood in this electrophoresis experiment was not of Fig. 3 The β-TG concentration after circulation on NF and BG in vitro Fig. 4 The molecular weights of the proteins adsorbed on NF and BG assessed by electrophoresis Fig. 5 The percent reduction of small molecules and low-molecularweight proteins in the blood before and after dialysis Fig. 6 The total amount of albumin in the effluent dialyzate hemodialysis patients, NF and BG would have approximately the same adsorption pattern even when the same experiment is performed on the blood of hemodialysis patients.) Comparing NF to BG in the clinical setting, the two dialyzers showed equivalent solute removal (Figs. 5 and 6 ). However, changes in the platelet count during dialysis confirmed reduced platelet adhesion to NF (Fig. 7) . It was considered that BG and NF have almost the same adsorption and fractionation characteristics, which suggested that the membrane structure of BG and NF are equivalent. The difference between the two membranes is only the electrostatic charge (Table 1) . Since NF has a less negative charge than BG, the electrostatic interaction between NF and platelets might be reduced. This is considered to be the reason why platelet adhesion and activation was suppressed significantly on NF.
In this study, we evaluated peripheral circulation by SPP which is a method measuring non-invasively dermal microcirculation by using Laser Doppler imaging-based methods because there are many reports describing them being useful to evaluate peripheral circulation disturbance such as lower limb ischemia in hemodialysis patients [7, 8] . Evaluation of the SPP suggested that peripheral circulation was more stable during dialysis with NF (Fig. 8) . Additionally, dialysis-related side effects tended to be reduced in patients who continued using NF for 3 months (Fig. 9) . Previous articles have reported the improvements of various clinical symptoms with the conventional PMMA dialyzers [3] [4] [5] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Protein adsorption by PMMA membranes is considered one factor associated with these improvements. However, on BG, platelets also tend to adhere and be activated. Activated platelets induce the aggregation of platelets alone, platelets and leukocytes together, and platelets, leukocytes, and erythrocytes, which can interfere with peripheral circulation during dialysis [20, 21] . Deteriorated peripheral circulation causes dialysis-related side effects, including muscle cramps and abdominal pain during and after dialysis and fatigue after dialysis. Recently, the problem of dialysis-related side effects as factors affecting the prognosis of dialysis patients has gained attention from researchers [22] [23] [24] , who have tried to identify the importance of dialysis prescriptions for reducing side effects [5] . On the other hand, in dialysis patients, aggregates of platelets and leukocytes remain in the serum even after dialysis and are associated with poor prognosis of these patients [25] . Improved platelet activation in NF may be significant in improving the prognosis of patients, as well as reducing the frequency of side effects. 
